Vietnam Gets Price-Cut Promises From Austria, French Drug Makers
This article was originally published in PharmAsia News
Executive Summary
Vietnam says Austrian and French pharmaceutical companies have agreed to reduce the prices of the drugs they sell in Vietnam. Ebewe Pharma of Australia and Les Laboratoires Servier of France notified the Vietnam Drug Administration they would reduce the prices of antibiotics and drugs for treating cancer, diabetes and heart diseases. The promised reductions covered 16 of Ebewe Pharma's 31 cancer drugs, some by as much as 12 percent. Servier promised a 7 percent reduction in the prices for two diabetes and heart drugs. (Click here for more)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.